biolitec AG:biolitec AG achieved consolidated sales of Euro 30.5 million for the fiscal year 2008/2009 - EBIT amounts to Euro 0.31 million

biolitec AG / Final Results

30.09.2009 

Dissemination of an Ad hoc announcement according to § 15 WpHG,
transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

biolitec AG achieved consolidated sales of Euro 30.5 million for the fiscal
year 2008/2009 - EBIT amounts to Euro 0.31 million

Jena, September 30, 2009 - biolitec AG, Jena, listed in  the Prime Standard
of the Frankfurt stock exchange (ISIN DE0005213409), generated consolidated
sales of 30.5 million for the fiscal year 2008/2009 (previous year: Euro
35.4  million). The decrease in turnover in particular is due to the
current economic crisis in the USA and Europe. The unfavorable investment
climate worldwide, the low US dollar exchange rate and the reticence of the
economic operators fearing an ongoing recession have decreased sales in
2008/2009 by about 14 percent compared to the previous year.

The gross profit amounted to Euro 21.4 million (previous year: Euro 23.9
million) and the EBIT Euro 0.31 million. R&D expenditures amounting to Euro
3.2 million in the fiscal year 2008/2009 (14 percent of the sales) remained
on a high level, but have been reduced by Euro 1.84 million compared to the
previous year. In the development and market launch of new products
significant progress has been achieved. Due to the initiated restructuring
measures, in this fiscal year a net income of Euro 0.64 million (previous
year: Euro 1.98 million) could be generated despite the still high R&D
expenditures and the decline in sales. Liquid assets are over Euro 6
million at the end of the fiscal year.

The sector optical fibers/ laser probes in 2008/2009 with over Euro 20
million remained around the previous year's level with only slight losses
(-5 percent). The turnover of the laser segment with Euro 8 million was
significantly lower than in the previous year, primarily because of the
recession in the US markets and Europe. In the pharma sector biolitec could
register an increase in turnover by 21 percent up to Euro 1.7 million. Main
roles in generating turnover still play the treatments of the benign
prostatic hyperplasia (BPH) LIFE(TM) and the endoluminal treatment of veins
(ELVeS(TM)).

The essential turnovers of biolitec have been generated in Europe and North
America. The turnover in North America amounted to Euro 11 million and so
was significantly lower than in the previous year. Sales in Europe were
Euro 15.5 million (previous year: 17.9 million). In Asia / Rest of the
World, biolitec could significantly increase turnover by 43 percent. In
South America and the Middle East, affiliates founded in 2008 already are
profitable and contribute to turnover.

biolitec expects sales growth to resume for this fiscal year. 


30.09.2009  Financial News transmitted by DGAP

---------------------------------------------------------------------------
 
Language:     English
Company:      biolitec AG
              Winzerlaer Straße 2a
              07745 Jena
              Deutschland
Phone:        +49 (0) 3641 508 550
Fax:          +49 (0) 3641 508 599
E-mail:       info@biolitec.de
Internet:     www.biolitec.de
ISIN:         DE0005213409
WKN:          521340
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, München, Düsseldorf, Stuttgart, Hamburg
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------